Drug Trial Radar · NCT01582321
Investigation of the Influence of Gender on Cardiovascular Function
Last checked: Nov 19, 2026Latest source record: Jun 14, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
56
Planned (sponsor's estimate)
Start
Mar 2012
Primary completion
Dec 2016
Study completion Jan 2017
Sponsor
- Lead sponsor
- Queen Mary University of LondonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 20, 2012
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Inflammation is a key initiating and damaging factor in many illnesses including infection, arthritis and cancer but also of particular relevance to this study in diseases of the heart and blood vessels (i.e. cardiovascular disease). Much evidence now exists demonstrating that male sex increases ones risk of cardiovascular disease. More recent evidence demonstrates that inflammatory responses in females appear to dampened in comparison to age matched males. Since inflammation is thought to be a key initiating phenomenon in many cardiovascular disease states the investigators will examine the differences in acute inflammatory responses between the sexes in healthy volunteers and the impact this has on the function of blood vessels.
Conditions
- Cardiovascular Function
Interventions
Typhoid vaccineBiological
The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution
CantharidinDrug
0.1% cantharidin solution in acetone from 0.7% stock solution of cantharone is prepared and applied immediately. 10 μl of cantharidin per disc.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Comparison change in blister fluid total and differential leukocyte numbers (Part 1)Time frame: 24, 72 h
- Flow-mediated dilatation (Part 2)Time frame: 0, 24, 48 h
Locations
1 site in 1 country. Site status is shown where the registry gives one.
William Harvey Heart Centre, Barts & The London Medical School
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.